Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway (NH-64), Rajpura, 140401, Punjab, India.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Inflamm Res. 2021 Jul;70(7):765-776. doi: 10.1007/s00011-021-01480-z. Epub 2021 Jul 1.
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.
非酒精性脂肪性肝病 (NAFLD) 是一种与多种代谢紊乱、肥胖和微生态失调相关的多方面疾病。肠道微生物群在 NAFLD 和其他代谢紊乱的发病机制中起着重要作用。然而，最近的科学热潮强调了有益的肠道微生物群和细菌疗法在 NAFLD 管理中的应用。粪便微生物群移植 (FMT) 是一种具有最新方法的现代治疗方法，可用于治疗 NAFLD。其他潜在的治疗方法包括益生菌和益生元补充剂，这些方法基于改变肠道微生物来治疗 NAFLD。在这篇综述中，我们的主要重点是肠道微生物群与 NAFLD 进展的病理关联、FMT 的历史方面和最新进展，以及可能干预措施来对抗 NAFLD 及其相关的代谢功能障碍。
